Citigroup’s Theriva Biologics TOVX Stock Holding History

Citigroup’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,391	Closed	-$272	–	6246
2026 Q1	$272	Sell	1,391 -4,798	-78%	-$946	﹤0.01%	5562
2025 Q4	$1.3K	Buy	6,189 +6,188	+618,800%	+$1.83K	﹤0.01%	5519
2025 Q3	$0	Buy	+1	New	–	﹤0.01%	6323
2025 Q1	–	Sell	-7,756	Closed	-$13.6K	–	5966
2024 Q4	$13.6K	Buy	+7,756	New	+$11.3K	﹤0.01%	5321
2018 Q4	–	Hold	0	–	–	–	7836
2018 Q3	–	Hold	0	–	–	–	7868
2018 Q2	–	Hold	0	–	–	–	7738
2018 Q1	–	Hold	0	–	–	–	7674
2017 Q4	–	Hold	0	–	–	–	7497
2017 Q3	–	Hold	0	–	–	–	7158
2017 Q2	–	Hold	0	–	–	–	7204
2017 Q1	–	Sell	-11	Closed	-$76.7K	–	7107
2016 Q4	$75K	Buy	11 +10	+1,000%	+$103K	﹤0.01%	5946
2016 Q3	$12K	Hold	1	–	–	﹤0.01%	6467
2016 Q2	$15K	Buy	+1	New	+$18.8K	﹤0.01%	6327
2016 Q1	–	Hold	0	–	–	–	7339
2015 Q4	–	Hold	0	–	-$3K	–	7864
2015 Q3	–	Hold	0	–	–	–	6936
2015 Q2	–	Hold	0	–	–	–	6575
2015 Q1	–	Hold	0	–	–	–	7078
2014 Q4	–	Hold	0	–	–	–	6741
2014 Q3	–	Hold	0	–	–	–	7299
2014 Q2	–	Hold	0	–	–	–	6959
2014 Q1	–	Hold	0	–	–	–	6895
2013 Q4	–	Hold	0	–	–	–	6792
2013 Q3	–	Hold	0	–	–	–	6537
2013 Q2	–	Hold	0	–	–	–	6460

Other funds holding TOVX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Citigroup's TOVX Position: Q2 2026 in Review

Citigroup sold out of Theriva Biologics (TOVX) in Q2 2026, closing a stake of 1,391 shares — an estimated $272 sold.

Citigroup first reported a position in TOVX in Q2 2016 and held it in 7 quarters. The position peaked at $75K in Q4 2016. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

Citigroup reported no remaining Theriva Biologics position as of Q2 2026 after selling out during the quarter.
Citigroup sold 1,391 Theriva Biologics shares in Q2 2026, an estimated $272.
Citigroup first reported a position in Theriva Biologics in Q2 2016 and held it in 7 quarters.
Citigroup's Theriva Biologics position peaked at $75K in Q4 2016.
26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.